← Back to Search

PET Imaging for Lung Cancer

Phase 2

Waitlist Available

Research Sponsored by American College of Radiology Imaging Network

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Planning treatment with definitive chemoradiotherapy

Histologically confirmed non-small cell lung cancer (NSCLC)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well a certain imaging test works in detecting disease progression and determining response to treatment in patients with locally advanced non-small cell lung cancer.

Who is the study for?

This trial is for adults with non-small cell lung cancer at stage IIB or III, who are planning to undergo chemoradiotherapy. They must be medically fit for the treatment and able to have PET imaging done. Pregnant women can't join, and those who can have children must use contraception during and after the trial.Check my eligibility

What is being tested?

The study is testing how well a special type of scan called ^18FDG-PET can detect disease progression in patients receiving chemoradiotherapy for advanced lung cancer. It aims to see if this scan helps doctors better predict treatment response.See study design

What are the potential side effects?

Since this trial focuses on imaging rather than medication, side effects are minimal but may include discomfort from lying still during the PET scan or reactions to the contrast agent used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am scheduled for combined chemotherapy and radiation treatment.

Select...

My lung cancer is confirmed to be non-small cell type.

Select...

My cancer is at stage IIB or III.

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Select...

I have received radiotherapy of 60 Gy or more and platinum-based chemotherapy at the same time.

Select...

I am 18 years old or older.

Select...

I am medically fit for intensive chemoradiotherapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Relationship of survival to post-treatment peak standardized uptake value (SUV) as determined by the imaging institution

Secondary outcome measures

Association between Ki-67 expression and overall survival at 2 years

Correlation of Ki-67 expression with peak and max pre-treatment SUV

Proportion of participants who are either upstaged or downstaged by positron emission tomography scan

+5 more

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

Radiation Therapy Oncology GroupNETWORK

190 Previous Clinical Trials

64,677 Total Patients Enrolled

American College of Radiology Imaging NetworkLead Sponsor

39 Previous Clinical Trials

466,625 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,932,903 Total Patients Enrolled

Media Library

Chemoradiotherapy Clinical Trial Eligibility Overview. Trial Name: NCT00083083 — Phase 2

Lung Cancer Clinical Trial 2023: Chemoradiotherapy Highlights & Side Effects. Trial Name: NCT00083083 — Phase 2

Chemoradiotherapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT00083083 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential hazards could arise from this course of treatment?

"This proposed treatment is judged to be moderately safe, ranking a 2 on our scale. This rating was given because the trial has only reached Phase 2 - there exists some data suggesting safety but none that demonstrate efficacy."

Answered by AI

Is there an opportunity to participate in this research experiment at the present time?

"The clinicaltrial.gov page for this study indicates that it is no longer actively recruiting patients, having been initially posted on March 1st 2005 and most recently updated February 26th 2011. Although inactive, there are 1628 other trials currently open to enrollment."

Answered by AI

How many venues are administering this experiment?

"Radiological Associates of Sacramento Medical Group at Sutter Cancer Center in California, Roger Williams Medical Centre in Rhode island and Albert Einstein Cancer Centre in Pennsylvania are a few out of 50 trial locations offering this medical study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

2005. "Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00083083.

All > Lung > Sclc